CollPlant Biotechnologies Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of September 2025. CollPlant Biotechnologies Ltd., a foreign private issuer based in Rehovot, Israel, reports a voluntary transfer of its ordinary share listing from the Nasdaq Global Market to the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
- Listing Transfer: On September 10, 2025, Nasdaq approved the Company's application to transfer its listing to the Nasdaq Capital Market.
- Trading Status: Trading of ordinary shares under the symbol "CLGN" began on the Nasdaq Capital Market on September 12, 2025.
- Market Continuity: The transfer does not affect trading operations, which continue in substantially the same manner as the previous market tier.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to notify the SEC of the approved listing transfer.
Investor Verification Checklist
- Confirm the effective date of the listing transfer (September 12, 2025).
- Verify that the stock ticker symbol remains "CLGN".
- Review the Nasdaq Capital Market listing requirements to understand the implications of the tier change.
- Check subsequent filings for any financial data or operational updates not included in this 6-K.